Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. Alexza has five other product candidates in various stages of clinical development. On August 26, 2009, Alexza completed the acquisition of Symphony All
[Blocked Image: http://img341.imageshack.us/img341/9272/d70394d7039401.gif]
_____________________________________________________
Total analysts: 4
Average consensus: 1.75 (Buy)
Buy : 1 25.00 %
Outperform : 3 75.00 %
_____________________________________________________
Target Price
Mean estimate : 7.25$
Median estimate : 6.50$
High estimate : 12.00$
Low estimate : 4.00$
_____________________________________________________
[Blocked Image: http://img375.imageshack.us/img375/6748/unbenanntv.png]
[Blocked Image: http://img688.imageshack.us/img688/8601/unbenanntjm.th.png]
Quote:
QuoteDuring their most recent Earnings Release and Conference Call on May 11, 2010, ALXA announced that they currently have enough money to fund their planned operations through the second quarter of 2011. If milestones are met under the Biovail Corporation deal, they will have enough money to fund their operations into 2012. As of March 31, 2010, ALXA has 40 million dollars in consolidated cash, cash equivalents and marketable securities. On May 5, 2010, ALXA executed a 15 million dollar loan with Hercules Technology Growth Capital. ALXA is also eligible for up to 90 million dollars in milestones payments from Biovail Laboratories, explained below.Alexza Pharmaceuticals partnered with Biovail Corporation, Canada's single largest pharmaceutical company, operating internationally in all aspects of pharmaceutical products. In February 2010, Alexza established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada. Under the terms of the collaboration, Alexza is entitled to receive an upfront cash payment of $40 million, up to $90 million in potential milestone payments contingent on the successful approval of the AZ-004 NDA and other milestones
The Staccato System (Drug-Vaporizer):
